Sector intelligence and perspective

BioTime (NYSEMKT: BTX) Submits CE Mark Application for EU Approval of Renevia®

March 13, 2018

Shares jump +$0.22 or +8.24% to $2.89

Caladrius Biosciences (CLBS) Doses1st patient with CLBS12 in P2 Critical Limb Ischemia (CLI) Trial in Japan

March 13, 2018

... In CLBS’ P2 clinical trial is for the treatment of no-option CLI. The stock is up +$0.19 or +3.39% to $5.80 – SELL into strength and news while reviewing the technicals and chart …

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.